8-K
filed June 14, 2023, 7:59 PM ET
ticker REGN
CIK 0000872589
other
confidence high
sentiment neutral
materiality 0.20
Regeneron shareholders re-elect all four Class II directors; bylaw amended to allow Co-Chairs
REGENERON PHARMACEUTICALS, INC.
- Joseph Goldstein, Christine Poon, Craig Thompson, Huda Zoghbi elected as Class II directors at June 9 annual meeting.
- Say-on-pay advisory vote approved (97.8M for, 14.5M against).
- Shareholders selected one-year frequency for future say-on-pay votes (111.2M votes).
- Non-binding proposal on access-to-medicine report rejected (10.6M for, 101.4M against).
- Bylaw amended to permit Board to elect two Co-Chairs, either of whom can exercise full powers.
Key facts
Extracted from this filing and checked against the source text.
Governance Changes
SEC 8-K Item 5.03/5.05/5.06
confidence 0.9
REGENERON PHARMACEUTICALS, INC.: Amendment to by-laws to permit election of two Co-Chairs of the Board, with either Co-Chair able to exercise full powers (effective 2023-06-09).
- Change
- bylaw amendment
- Effective
- 2023-06-09
Exact text from the filing
The Amendment provides that the Board from time to time may elect two persons to serve as Co-Chairs of the Board and that, if there are Co-Chairs, either Co-Chair may exercise the full powers and authorities of the office.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
REGENERON PHARMACEUTICALS, INC. shareholders approved Election of Class II directors at the 2023-06-09 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-06-09
Exact text from the filing
Proposal 1 – Election of Directors The following nominees for Class II directors were elected to serve until the 2026 Annual Meeting of Shareholders and until their successors are duly elected and qualified based upon the following votes: Nominee For Against Abstain Broker Non-Votes Joseph L. Goldstein, M.D. 78,930,855 33,390,357 196,082 4,209,777 Christine A. Poon 84,515,116 27,751,062 251,116 4,209,777 Craig B. Thompson, M.D. 111,784,253 644,879 88,162 4,209,777 Huda Y. Zoghbi, M.D. 108,341,947 4,126,763 48,584 4,209,777
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
REGENERON PHARMACEUTICALS, INC. shareholders rejected Non-binding shareholder proposal requesting report on process by which access to medicine is considered in matters related to protecting intellectual property at the 2023-06-09 meeting.
- Outcome
- failed
- Meeting
- 2023-06-09
Exact text from the filing
Proposal 5 – Non-binding Shareholder Proposal Requesting Report on a Process by which Access to Medicine is Considered in Matters Related to Protecting Intellectual Property The non-binding shareholder proposal requesting report on a process by which access to medicine is considered in matters related to protecting intellectual property was not approved based upon the following votes: For: 10,554,422 Against: 101,359,081 Abstain: 603,791 Broker Non-Votes: 4,209,777
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory vote to approve the compensation of named executive officers at the 2023-06-09 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2023-06-09
Exact text from the filing
Proposal 3 – Advisory Vote on Executive Compensation The resolution to approve, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement was approved based on the following votes: For: 97,786,842 Against: 14,490,406 Abstain: 240,046 Broker Non-Votes: 4,209,777
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
REGENERON PHARMACEUTICALS, INC. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year 2023 at the 2023-06-09 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-06-09
Exact text from the filing
Proposal 2 – Ratification of Appointment of Independent Registered Public Accounting Firm The proposal to ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023, was approved based upon the following votes: For: 112,392,480 Against: 4,290,618 Abstain: 43,973
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.95
REGENERON PHARMACEUTICALS, INC. shareholders approved Advisory vote on the frequency of future advisory votes on executive compensation at the 2023-06-09 meeting.
- Proposal
- say on pay frequency
- Outcome
- passed
- Meeting
- 2023-06-09
Exact text from the filing
Proposal 4 – Advisory Vote on Frequency of Future Advisory Votes on Executive Compensation One year was selected by a majority of the votes cast on the advisory proposal on the frequency of future advisory votes on executive compensation based upon the following votes: One Year: 111,204,155 Two Years: 56,571 Three Years: 1,192,972 Abstain: 63,596 Broker Non-Votes: 4,209,777
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.